Prognostic Value of Tumor Hypoxia, as Measured by 18F-FMISO Breath Hold PET/CT, in Non-Small-Cell-Lung Cancer (NSCLC) Patients



Status:Active, not recruiting
Conditions:Lung Cancer, Lung Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:8/12/2018
Start Date:December 16, 2013
End Date:December 2019

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria
The purpose of this study is to help researchers investigate if a new imaging agent named
18F-FMISO can predict if patients with lung cancer will respond to standard therapy, as well
as whether disease will reoccur in the future. The study will also investigate whether a
18F-FDG PET scan in the middle of radiation treatment can predict if lung cancer will respond
to standard therapy. Information obtained from this study may help doctors design future
studies in which they may target tumor areas that do not respond to therapy or may likely
reoccur in the future.


Inclusion Criteria:

- Pathologic confirmation of NSCLC at MSKCC

- No prior treatment for this diagnosis of NSCLC

- Patient to be treated with neoadjuvant chemotherapy (35 patients total) or patient to
be treated with definitive RT,sequential chemo-RT, or concurrent chemo-RT (minimum
dose of 50 Gy in 25 fractions) (25 patients total)

- Tumor must measure ≥ 2cm on CT

- Age ≥ 18 years

- Ability to hold the breath for 10 seconds.

- Karnofsky performance status ≥ 70%

- Women of childbearing age must have a negative blood pregnancy test

Exclusion Criteria:

- Women who are pregnant or breast-feeding

- Severe diabetes (fasting Blood Glucose > 200 mg/dl)
We found this trial at
1
site
Memorial Sloan Kettering Cancer Center
1275 York Ave
New York, New York 10021
(212) 639-2000
Principal Investigator: Andreas Rimner, MD
Phone: 212-639-6025
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
?
mi
from
New York, NY
Click here to add this to my saved trials